Regeneron Pharmaceuticals said Friday it has paused a clinical study of its antibody drug to treat some of the sickest COVID-19 patients because of a potential safety concern.

The recommendation from an independent monitoring board marks the second time a clinical trial of an experimental coronavirus antibody drug has been paused because of safety issues.

Regeneron said it is pausing enrollment of hospitalized COVID-19 patients receiving mechanical ventilation or intense oxygen after the independent monitoring committee observed “a potential safety signal and an unfavorable risk/benefit profile at this time.”

[link to thehill.com (secure)]